A Non Interventional Pilot Study on Machine Learning for ILD Detection Based on the Patient Data From Digital Devices in Unresectable Stage III Non-Small Cell Lung Cancer Patients Receiving Durvalumab
Latest Information Update: 29 May 2023
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms iDETECT
- Sponsors AstraZeneca
Most Recent Events
- 24 May 2023 Status changed from active, no longer recruiting to completed.
- 16 Feb 2023 Planned End Date changed from 31 Dec 2022 to 30 Apr 2023.
- 16 Feb 2023 Planned primary completion date changed from 31 Dec 2022 to 30 Apr 2023.